All In Biotech

Drug Trial Radar · NCT06319794

Study on the Safety and Efficacy of Bimiralisib Gel in Participants Suffering From Actinic Keratosis

A Randomized Phase 2 Proof-of-Concept Study to Evaluate the Efficacy and Safety of Topical Bimiralisib Application in Participants Suffering From Actinic Keratosis on the Face and/or Scalp and/or Back of Hands Over a 2 and 4-week Treatment Period

Last checked: Nov 19, 2026Latest source record: Jul 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

46

Actual

Start

Apr 2, 2024

Primary completion

Jun 24, 2025

Study completion Jun 24, 2025

Sponsor

Lead sponsor
TORQURIndustry
Sponsor type
Industry
First posted
Mar 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The aim of the study is to evaluate efficacy and safety of bimiralisib gel treatment for treatment of actinic keratosis (AK) on the face and/or scalp and/or back of hands

Conditions

  • Actinic Keratosis

Interventions

  • BimiralisibDrug

    Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 2 weeks

  • BimiralisibDrug

    Participants will be instructed to self-apply topical bimiralisib gel on the treatment area once daily for 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in AK lesions as measured by achieving an Investigator Global Assessment (IGA) score of 0 or 1Time frame: Baseline, Day 43 (Treatment Arm A), Day 57 (Treatment Arm B)

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital Basel / Department of Dermatology

    Basel, Switzerland

  • CHUV centre hospitalier universitaire vaudois / Department of Dermatology and Venereology

    Lausanne, Switzerland

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.